Actualités

These stocks pay between 4.2% and 6.7% in dividends.

If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.

AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.

Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 report dominated by a $9 billion Cidara acquisition charge. Two very different income stories for yield hunters. One Pays You to ... Pfizer vs Merck: Chasing High Yield vs Higher Returns

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.

Whichever one you choose, you'll need patience before you can see solid returns.

It is finally bouncing back after several challenging years.

Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal cancer and TALZENNA combination in metastatic hormone-sensitive prostate cancer, presented at ASCO 2026. The BREAKWATER trial of BRAFTOVI with cetuximab and FOLFIRI in BRAF V600E mutated metastatic colorectal cancer showed strong efficacy signals in progression-free and overall survival. The TALAPRO-3 study of TALZENNA with XTANDI in hormone-sensitive prostate cancer...

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks on this list. TheFly reported on May 27 that PFE and Innovent Biologics announced a global strategic licensing and collaboration agreement covering the research and development of 12 early-stage oncology programs, including […]

Pfizer (NYSE:PFE) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple. After running the numbers, my view leans constructive, and the 24/7 Wall St. price target reflects that. PFE stock trades at $26.18, and our 24/7 ... Why Pfizer’s Current Price May Be Too Cheap to Ignore

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 early stage cancer programs, including antibody drug conjugates and multi specific antibodies. The company also reported seven year follow up results from the Phase 3 CROWN trial, indicating sustained protection from LORBRENA against disease progression and brain metastases in ALK positive advanced lung cancer. Pfizer is currently trading at $26.18, with the stock up...

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.

Lawmakers and some investors are warning about the growing reliance of US pharmaceutical companies on China, raising the prospect of national...

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Pfizer Inc. and China’s Innovent Biologics have announced a global licensing and collaboration agreement. The deal, valued at up to $10.5 billion, is set to develop 12 early-stage cancer drugs. The agreement comprises an upfront payment of $650 million to...

Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

Pfizer and Innovent strike a global cancer-drug partnership as Chinese biotech licensing momentum accelerates.

Pfizer and Innovent signed a global oncology deal worth up to $10.5 billion.

LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.

The U.S. pharma giant will pay $650 million upfront to China's Innovent Biologics to co-develop 12 early-stage oncology programs

Innovent Biologics will receive $650m upfront and could earn up to $9.85bn in additional milestone payments.